Immunogenicity and safety of intradermal delivery of hepatitis B booster vaccine using the novel drug delivery device VAX-ID

• Published in: Vaccine Vol. 37; no. 4; pp. 581 - 586
• Main Authors: Van Mulder, T.J.S, Withanage, K, Beyers, K.C.L, Vankerckhoven, V.V.J, Theeten, H, Van Damme, P
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 21.01.2019; Elsevier Limited
• Subjects: Adolescent; Adult; Allergy and Immunology; Antigens; Booster; Device; Drug Administration Routes; Drug delivery; Drug delivery systems; Drug Delivery Systems - instrumentation; Drug dosages; Equipment Safety; Female; Forearm; Hepatitis; Hepatitis Antibodies - blood; Hepatitis B; Hepatitis B - prevention & control; Hepatitis B vaccine; Hepatitis B Vaccines - administration & dosage; Hepatitis B Vaccines - immunology; Humans; Immune response; Immune system; Immunization; Immunization, Secondary; Immunogenicity; Immunogenicity, Vaccine; Immunologic Memory; Injection; Injections; Injections, Intradermal; Injections, Intramuscular; Intradermal; Intramuscular; Male; Pain; Performance evaluation; Proof of Concept Study; Pruritus; Safety; Vaccination; Vaccination - instrumentation; Vaccination - methods; Vaccines; Young Adult; Hepatitis B vaccine; Intramuscular; Intradermal; Device; Booster
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2018.12.016

AbstractBackgroundAlthough intramuscular (IM) injection is still the most preferred method for vaccination, intradermal (ID) delivery may have several advantages over intramuscular and subcutaneous (SC), including an improved immune response and antigen dose sparing effect. However it is currently limited due to the difficulty in standardizing the injection technique often based on the Mantoux technique. Difficulties encountered using the Mantoux technique could be overcome by the use of alternative ID delivery systems that confer more uniform and standardized procedures. The aim of this study was to evaluate the performance of a newly developed intradermal injection device, VAX-ID™, via a proof-of-concept to assess the immunogenicity of a commercially available hepatitis B booster vaccination in healthy hepatitis B pre-immunised subjects. Additionally, device safety and tolerability was evaluated. Materials and methodsThree different routes of administration were compared over 4 groups, each receiving hepatitis B vaccine antigen: (1) standard IM injection in the deltoid region (HBVAXPRO® 10 µg/1 ml), (2) ID injection in the proximal posterior area of the forearm according to the Mantoux technique, (3) with VAX-ID™ in one forearm, or (4) with VAX-ID™ in both forearms. For ID injections 0.11 cc, of which 0.01 cc is overfill, was drawn from a vial containing HBVAXPRO® 40 µg/1 ml. Immunogenicity and safety were followed-up at day 0, 14, 30 and 210. ResultsA total of 48 subjects were included. All subjects showed an anamnestic response at 14 days post booster vaccination. Elevated titres persisted until end of follow-up at day 210. For the ID groups a 3 fold higher immune response at day 14 and day 30 was recorded compared to IM group. Local adverse events were more reported for ID compared to IM. ConclusionsThe investigated ID injection device VAX-ID™ proves to be a good alternative to offer ID vaccination.